INTRODUCTION AND OBJECTIVES: Sex steroid levels vary by geographic location suggesting environmental factors may influence hormone production. We used data from Reduction by Dutasteride in Prostate Cancer Events (REDUCE) trial to identify differences in baseline androgen levels and sexual function between North American and European men.
INTRODUCTION AND OBJECTIVES: A Risk Evaluation and
Mitigation Strategy (REMS) program was instituted for testosterone undecanoate because of the potential risk of pulmonary oil microembolism (POME) and/or anaphylaxis after intramuscular injection of testosterone undecanoate. This analysis examined the reporting rate of POME associated with the use of testosterone undecanoate (750 mg/ 3 mL) during postmarketing surveillance.
METHODS: The Endo Pharmaceuticals Inc database was searched for reports of POME occurring from the time of testosterone undecanoate approval on March 5, 2014 through June 30, 2018. Each case was reviewed and adjudicated by a drug safety physician to confirm that the reported event had predefined clinical characteristics consistent with POME.
RESULTS: During the 4.3-year period, 90,092 doses of intramuscular testosterone undecanoate were distributed via the REMS program to healthcare professionals for patient treatment. From a total of 633 individual case safety reports, 28 reported adverse events were classified as POME, for a calculated yearly perinjection POME rate of <0.1%. Of these 28 cases, 21 (75.0%) resolved, and for those with a resolution time reported, 13 of 16 (81.2%) resolved in 30 minutes. Thirteen of the 21 cases that resolved (61.9%) required no medical intervention (ie, POME event resolved spontaneously). One fatality was reported 18 months after a documented POME event and appeared unrelated to the reported testosterone undecanoate injection or subsequent injections received after the POME event. In 4 POME cases with symptoms serious enough to require an emergency room visit, issues with the injection technique, incorrect product usage, or a preexisting medical condition (asthma) were identified as contributing factors.
CONCLUSIONS: POME events in men treated with testosterone undecanoate are rare, nonserious, and resolve quickly without medical intervention in the vast majority of cases. Most emergency department visits for POME have been the result of injection-related errors, reinforcing the importance of proper technique to minimize the risk of drug injection into the venous circulation and subsequent development of rare adverse events like POME.
Source of Funding: Endo Pharmaceuticals Inc.
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Joseph Mahon*, MAYWOOD, IL; Sevann Helo, Minneapolis, MN; Joseph Ellen, Richmond, VA; Paul Fuestel, Charles Welliver, Albany, NY; Andrew McCullough, Burlington, MA INTRODUCTION AND OBJECTIVES: The use of selective estrogen receptor modifiers (SERM) and aromatase inhibitors (AI) have been used for decades for the treatment of secondary hypogonadism. While both have been shown to satisfactorily increase free and total testosterone (FT, TT) levels, the clinical benefit on sexual function is unclear. Minimal quality evidence is available for testosterone restoration, particularly with the utilization of validated questionnaires.
METHODS: Individuals with baseline TT 150-350 ng/DL on two hormone assays aged 18-70 yrs, positive baseline ADAM score, BMI <40 and SHIM >7 and <21 were eligible to be randomized to AI, SERM or placebo for 8 weeks in a cross-over fashion for a total study duration of 24 weeks.
Hormone assays (TT, FT, LH, FSH, and SHBG) and questionnaire data (ADAM, IIEF, EHS) were collected at baseline and at the conclusion of each 8 week study arm.
The primary outcome was an improvement of þ4 in the erectile function domain of IIEF response after 8 weeks of treatment compared to placebo. Secondary outcomes included: normalization of TT, decreased affirmative responses to ADAM, and improved EHS.
RESULTS: The average age was 45.8 years (range 29-63). Drug agents improved TT to a eugonadal range with SERM reaching higher mean levels than AI þ124.1 (95% CI 24.0, 224.1), p[0.01.
While a trend towards improvement in ADAM response and the overall satisfaction domain of IIEF were noted for SERM vs. screening; no statistically significant changes in EHS or the other IIEF domains were noted with either drug versus placebo. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e853
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